Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534595 | 0.87 | GPR119 (0.54) | GPR119 | |
| SCHEMBL8512886 | 0.87 | CHRNA7 (0.34) | GPR119CDK2 | |
| SCHEMBL9266102 | 0.84 | GPR119 (0.48) | GPR119 | |
| SCHEMBL8531977 | 0.84 | GPR119 (0.49) | GPR119CHEK2 | |
| SCHEMBL15253061 | 0.83 | GPR119 (0.38) | GPR119 | |
| SCHEMBL8586479 | 0.83 | CHRNA7 (0.39) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15259313 | 0.83 | CETP (0.40) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9265460 | 0.78 | PRKCZ (0.38) | KDM1A | |
| SCHEMBL9262487 | 0.77 | GPR119 (0.53) | GPR119 | |
| SCHEMBL3297269 | 0.76 | MAP4K4 (0.49) | GPR119NR1H2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | GPR119 1/4885CHEK2 3915/4885KDM1A 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.